{"title":"罕见的her2阳性纯乳腺化生鳞状细胞癌1例。","authors":"Lingping Xie, Tianhai Du, Chao Wang","doi":"10.1007/s12672-025-03107-9","DOIUrl":null,"url":null,"abstract":"<p><p>Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"1340"},"PeriodicalIF":2.9000,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263529/pdf/","citationCount":"0","resultStr":"{\"title\":\"A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast.\",\"authors\":\"Lingping Xie, Tianhai Du, Chao Wang\",\"doi\":\"10.1007/s12672-025-03107-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.</p>\",\"PeriodicalId\":11148,\"journal\":{\"name\":\"Discover. Oncology\",\"volume\":\"16 1\",\"pages\":\"1340\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2025-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263529/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Discover. Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12672-025-03107-9\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-03107-9","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
A rare case of HER2-positive pure metaplastic squamous cell carcinoma of the breast.
Primary squamous cell carcinoma of the breast (PSCCB) is a rare form of metaplastic breast carcinoma (MpBC), constituting approximately 0.1% of all invasive breast cancers. It is characterized by unique morphological and clinical features, exhibiting a high degree of invasiveness and a poor prognosis. Most molecular subtypes are negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), while HER2-positive PSCCB is even rarer, accounting for approximately 4-22% of cases. Accurate histological diagnosis is crucial for effective management.Currently, there is limited research on neoadjuvant chemotherapy combined with targeted therapy for HER2-positive PSCCB, and standardized treatment protocols have yet to be established. We report a case of pure HER2-positive PSCCB with the aim of gaining experience in the treatment of HER2-positive PSCCB.